Medica S.p.A.

Equities

MDC

IT0005460149

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-04-26 am EDT			5-day change	1st Jan Change
26.4 ^EUR	0.00%		+0.76%	+70.32%

Apr. 26	Response Plus Unit Closes Prometheus Medical Acquisition	MT
Apr. 19	ITALY GROWTH WINNERS & LOSERS: Medica bullish; Plants in the red.	AN

Medica Group fails to re-tender for new screening contract

May 26, 2023 at 09:48 am EDT

Medica Group PLC - Hastings, England-based provider of services such as x-ray and MRI scan analysis to hospitals - Notes failure to re-tender for a new diabetic retinopathy screening contract in Ireland. Says it is evaluating its response, but expects time needed for services to transition to a new provider. Anticipates no material adverse impact on its revenue and profit in 2023. Notes it does not have to pay EUR1.6 million to the sellers of Medica Ireland, formerly Global Diagnostics Ireland. Further, reports "strong growth" in its core radiology services business line in 2022 as well as outperformance of its own year-to-date revenue expectations across its scanning and reporting services. For 2023, the company says it remains "well-positioned for growth".

Current stock price: 211.25 pence, up 0.1% on Friday

12-month change: up 36%

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Medica S.p.A.

Response Plus Unit Closes Prometheus Medical Acquisition	Apr. 26	MT
ITALY GROWTH WINNERS & LOSERS: Medica bullish; Plants in the red.	Apr. 19	AN
Donaldson Company, Inc. made an offer to acquire Medica S.p.A. for ?22.9 million.	Apr. 18	CI
Substrate Artificial plans three AI-focused IPOs; eyes swing to profit	Apr. 11	AN
Medica S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Medica, profit falls in 2023 despite strong revenue growth	Mar. 25	AN
Mib advances; Leonardo and Ferrari on yearly highs	Mar. 25	AN
Futures down; new credit line for Pirelli	Mar. 25	AN
Mib up tepidly; sell-off on Webuild	Mar. 22	AN
India's Manipal Health set to buy majority stake in Medica Synergie for $151 million, source says	Mar. 14	RE
Beewize on sprint; Olidata down	Feb. 09	AN
Medica, FDA clears marketing of hemoconcentrators in U.S.	Feb. 08	AN
Olidata invests in digital healthcare by taking over 40 percent of Per Te	Feb. 06	AN
Medica closed 2023 with sharply increased revenues	Feb. 06	AN
Squares bullish; purchases on UniCredit and Azimut	Feb. 06	AN
Stock markets bullish; strong push on Asian stocks	Feb. 06	AN
UniCredit pushes Mib up, only bullish in Europe	Feb. 05	AN
CS Medica Obtains Danish Patent for Wound Healing Gel	Feb. 02	MT
CS Medica Set to Launch Pain Patch, Cosmetic Products in Australia	Jan. 26	MT
Medica strengthens in China, bought out 20 percent of China's Medico MedTech	Jan. 15	AN
Altamira Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders Equity Requirement	Nov. 29	MT
Jiang Zhong Pharmaceutical to Buy Two Local Firms for 13.5 Million Yuan	Nov. 27	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	Nov. 17	MT
Top Midday Gainers	Nov. 17	MT
Altamira Therapeutics to Sell 51% of Bentrio Maker for $2.3 Million	Nov. 17	MT

Chart Medica S.p.A.

Duration

Period

More charts

Company Profile

Medica SpA is an Italy-based company primarily engaged in designing, manufacturing and supplying blood purification systems. Through subsidiaries, such as Tecnoideal sel the Company not only offers dialyzers, ultrafilters, HDF online sets, bloodlines, and pediatric dialyzers for dialysis treatment but also provides critical care CRRT equipment, hemofilter, pediatric filters, C02 removal, apheresis equipment, fractionator-cascade filtration, plasma filters, and leukocyte adsorber. It also supplies Cardiosmart, an integrated system for the treatment of patients affected by congestive heart failure; MediSulfone membrane and Purema hemoconcentration. It is engaged in water purification offering systems, including lab-pharma-industrial filtrations, individual water purifiers, and point-of-use filtrations. The Company provides infusion sets, urodynamic systems, palm bladder scanner and gastroenterology systems, among others. It operates globally.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Ratings for Medica S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.4 EUR

Average target price

31.4 EUR

Spread / Average Target

+18.94%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDICA S.P.A.	+70.32%	119M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research